Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
9499 studies found for:    "Growth Substances"
Show Display Options
Download search resultsDownload the search results for:
"Growth Substances" (9499 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
Conditions: Metastatic Hepatocellular Carcinoma;   Advanced Liver Cancer
Interventions: Drug: Ascorbic Acid + Sorafenib;   Drug: Sorafenib alone
2 Completed Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
Condition: Stage IV Pancreatic Cancer
Intervention: Drug: Ascorbic Acid
3 Terminated Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Condition: Stage IV Colorectal Cancer
Intervention: Drug: Vitamin C
4 Terminated Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
Conditions: Neuroendocrine Tumors;   Pancreatic Neoplasms;   Advanced Disease;   Sunitinib
Intervention: Drug: Sutent
5 Terminated Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma
Conditions: Hepatocellular Carcinoma;   Fibrolamellar Hepatocellular Carcinoma
Intervention: Drug: Sutent
6 Completed Trial of Vitamin D Supplementation for the Prevention of Influenza and Other Respiratory Infections (ViDiFlu)
Conditions: Respiratory Tract Infections;   Influenza
Interventions: Dietary Supplement: Cholecalciferol (Vitamin D/Vigantol oil);   Dietary Supplement: Miglyol oil
7 Terminated Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Conditions: Hepatocellular Carcinoma Non-resectable;   Hepatocellular Carcinoma Recurrent;   Carcinoma, Hepatocellular;   Liver Diseases;   Neoplasms by Histologic Type;   Digestive System Neoplasms;   Carcinoma;   Liver Neoplasms;   Neoplasms;   Neoplasms by Site;   Digestive System Diseases;   Adenocarcinoma;   Neoplasms, Glandular and Epithelial
Interventions: Drug: ABT-869;   Drug: Sorafenib
8 Completed Patellar Tendon Regeneration With Platelet-rich Plasma
Condition: Knee Instability
Interventions: Procedure: Platelet-rich plasma;   Procedure: Control group
9 Terminated Growth Hormone and Heart Failure
Condition: Heart Failure, Congestive
Intervention:
10 Completed A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy
Conditions: HIV Infections;   Peripheral Nervous System Disease
Intervention: Drug: Nerve Growth Factor, Recombinant Human
11 Not yet recruiting Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability
Conditions: Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Microsatellite Instability;   Stage IIIA Colon Cancer;   Stage IIIB Colon Cancer;   Stage IIIC Colon Cancer
Interventions: Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
12 Not yet recruiting Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure
Condition: Allergic Asthma
Interventions: Drug: gamma tocopherol;   Drug: Placebo
13 Not yet recruiting Phase I/II Study of Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R(2)) In Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma
Conditions: Primary Effusion Lymphoma;   B-Cell Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Rituximab;   Drug: Prednisone;   Drug: Etopside;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide on day 10 (for 6 cycles), each patient will get a 750 mg/m2 dose.
14 Not yet recruiting Lipoic Acid Supplement for Cystine Stone
Condition: Cystinuria
Interventions: Dietary Supplement: Alpha lipoic acid;   Drug: Placebo
15 Recruiting Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Epirubicin 90 mg/m2 iv;   Drug: Cyclophosphamide 600 mg/m2 iv;   Drug: Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv;   Drug: Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only);   Drug: Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only);   Dietary Supplement: Tocotrienol 300 mg x 3 daily
16 Not yet recruiting Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis
Conditions: Peritoneal Dialysis (PD);   Anemia;   Chronic Kidney Disease
Intervention: Drug: Triferic
17 Recruiting Impact of Time Intervals of Preparation on Quality and Tolerance of the Bowel Preparation
Conditions: Bowel Preparation;   Colonoscopy
Intervention: Procedure: Colonoscopy
18 Recruiting Effect of Folic Acid on Skin Fungal Pattern in Patients With Arsenicosis
Condition: Chronic Arsenic Poisoning
Interventions: Drug: Iron 200 mg;   Drug: Folic acid 5 mg
19 Not yet recruiting Rectal Misoprostol in Women Undergoing Myomectomy for Intraoperative Blood Loss: A Randomized Placebo-controlled Study
Condition: Misoprostol, Blood Loss, Myomectomy
Interventions: Drug: Rectal Misoprostol;   Drug: Placebo
20 Recruiting Randomized Phase II Trial of Chemoembolization and Sorafenib
Condition: Hepatocellular Carcinoma
Interventions: Drug: conventional TACE in combination with sorafenib, administered on a continuous schedule;   Drug: conventional TACE in combination with sorafenib, administered on a sequential schedule

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years